Merck & Co./MRK
$131.19
0.23%-
1D1W1MYTD1YMAX
About Merck & Co.
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.
Ticker
MRK
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology & Drugs
CEO
Robert Davis
Employees
72,000
Headquarters
Rahway, United States
Website
www.merck.com
Merck & Co. Metrics
BasicAdvanced
$332B
Market cap
147.06
P/E ratio
$0.89
EPS
0.41
Beta
$3.00
Dividend rate
2.35%
Dividend yield
Price and volume
Market cap
$332B
Beta
0.41451
52-week high
$133.10
52-week low
$99.14
Average daily volume
8.2M
Dividend rate
$3.00
Financial strength
Current ratio
1.253
Quick ratio
0.993
Long term debt to equity
77.153
Total debt to equity
84.776
Dividend payout ratio (TTM)
331.66%
Interest coverage (TTM)
6.55%
Management effectiveness
Return on assets (TTM)
2.17%
Return on equity (TTM)
5.29%
Return on investment (TTM)
2.81%
Valuation
Price to earnings (TTM)
147.061
Price to revenue (TTM)
5.412
Price to book
8.232
Price to tangible book (TTM)
206.256
Price to free cash flow (TTM)
94.991
Five year average dividend yield
2.85%
Dividend yield (TTM)
2.29%
Forward dividend yield
2.35%
Growth
Revenue change (TTM)
6.11%
Earnings per share change (TTM)
-82.59%
3-year revenue growth
13.13%
3-year earnings per share growth
-56.81%
3-year dividend per share growth
6.08%
What the Analysts think about Merck & Co.
Analyst Ratings
Majority rating from 27 analysts.
Price Targets
Average projection from 25 analysts.
High $155.00
Low $118.00
$131.19
Current price
$141.42
Average price target
Merck & Co. Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$16B
7.83%
Net income
$4.8B
-488.42%
Profit margin
30.18%
-460.14%
Merck & Co. Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.06
$2.13
$0.03
$2.07
-
Expected
-$2.18
$1.95
-$0.11
$1.88
$2.14
Surprise
-5.39%
9.17%
-127.48%
10.4%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $332B as of May 20, 2024.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 147.06 as of May 20, 2024.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of May 20, 2024, the dividend rate is $3 and the yield is 2.35%. Merck & Co. has a payout ratio of 331.66% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment date is unconfirmed.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the Merck & Co. stock price target?
The target price for Merck & Co. (MRK) stock is $141.42, which is 7.8% above the current price of $131.19. This is an average based on projections from 25 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Merck & Co. stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.